Methotrexate

SAN DIEGO — In this video, Healio spoke with Kathryn Dao, MD, about the SMART study presented at ACR Convergence 2023.

SAN DIEGO — Split-dose methotrexate had greater efficacy and reduced the need for additional disease-modifying antirheumatic drugs at 16 weeks vs. a single dose for rheumatoid arthritis, according to data presented at ACR Convergence 2023.

PHILADELPHIA — Pegloticase and methotrexate can be used to reduce blood pressure in patients with gout, hinting at a link between serum uric acid level and hypertension, according to data presented at the ASN Kidney Week conference.

Both methotrexate and cyclosporin are efficacious in the treatment of severe pediatric atopic dermatitis, but methotrexate showed higher rates of sustained treatment response, according to a study.

Patients who receive pegloticase alongside methotrexate for gout demonstrate higher response rates and fewer discontinuations, and were more likely to achieve tophi resolution, vs. those treated with pegloticase alone, according to data.

Patients with muscle-invasive bladder cancer receiving dose-dense methotrexate, vinblastine, doxorubicin and cisplatinhad improved OS at 5 years compared with gemcitabine and cisplatin, according to a presentation at ASCO Annual Meeting.

Children with Cogan’s syndrome should undergo thorough evaluations upon presentation, including screenings for autoimmune and infectious diseases, as well as echocardiography and brain MRI, according to data.

Patients with rheumatoid arthritis who demonstrate lower disease activity are more likely to remain in LDA or remission after switching from combination therapy to monotherapy, according to data published in the Journal of Rheumatology.

In a panel-led project, 23 experts created a comprehensive guide for the long-term management of inflammatory skin diseases in pediatric patients treated with methotrexate.

In this video, Kathryn Dao, MD, associate professor in the department of internal medicine’s division of rheumatology at UT Southwestern Medical Center, discussed interesting new treatments on the horizon for RA, including new JAK inhibitors under development and a “scorpion venom toxin” with potential utility.